newsfilter
← Latest News
PR Newswire·

A subgroup analysis of Medivir's phase II study of MIV-711 for osteoarthritis shows statistically significant reduction in OA pain

STOCKHOLM, Feb. 28, 2022 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR) today announces that an article entitled "Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis o